跳至主要内容
临床试验/ITMCTR2024000133
ITMCTR2024000133招募中2 期

Fuzheng Kangai Formula combined with first-line immunotherapy for non small cell lung cancer patients with middle or advanced stage: A retrospective study

Guangdong provincial hospital of Chinese medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 80(—)
性别
All

入选标准

  • 1) Patients who were pathologically and clinically diagnosed as an IIIA or IVB stage non-small cell lung cancer with at least one measurable lesion.
  • 2) Patients who have been received at least 2 cycles of first line immunotherapy either alone or in combination with multiple therapies.
  • 3) A outcome measure for evaluation.
  • 4) Age was limited from 18 to 80 years old. Other baseline characteristics such as sex, PS score and PD-L1 expression were not limited.

排除标准

  • 1) Multiple primary malignancies coexist.
  • 2) Case-related information is incomplete or unavailable

研究者

发起方
Guangdong provincial hospital of Chinese medicine

相似试验